GLP-1 (glucagon-like peptide 1) medications are revolutionizing weight loss and diabetes care, but behind the hype lies a growing web of regulatory gaps, telehealth expansion and online pharmacy risks. This episode unpacks the opportunities -- and dangers -- shaping the future of these life-changing drugs.

 

Featuring: Scott Roth, Chief Executive Officer, LegitScript

Gerard Olsen, Director of Research, LegitScript

 

In today’s episode, we'll cover…

• The skyrocketing demand for GLP-1 medications and their influence on weight loss trends, including a 26% drop in bariatric surgeries
• How telehealth and online pharmacies are reshaping access to GLP-1 drugs -- and the risks posed by rogue sellers and counterfeit products
• The critical need for stronger regulatory enforcement and LegitScript's role in ensuring safety and transparency in the online healthcare market

 

To learn more about GLP-1 medications from all angles, check out our Pharma Life Sciences, Patient Engagement and Healthcare Payers sites.

 

To watch video clips from the conversation, subscribe to our YouTube channel, @HealthcareStrategies.

 

References:

Metabolic bariatric surgery in the GLP-1 era (https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2825349)

 

Risks of online semaglutide without prescription (https://www.techtarget.com/pharmalifesciences/news/366609735/Study-uncovers-risks-of-buying-semaglutide-online)

 

FDA updates on GLP-1 compounding policies (https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize)